Boundless Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary

Boundless Bio

07/08/2026 13:31

Boundless Bio, Inc. BOLD.OQ reported a quarterly adjusted loss of $1.06​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -70 cents.  The lone analyst forecast for the quarter was for a loss of 58 cents per share. 
Reported revenue was zero​; analysts expected zero. 
Boundless Bio, Inc.'s reported EPS for the quarter was a loss of $1.06​.
The company reported a quarterly loss of $23.69 million.
Boundless Bio, Inc. shares had risen by 13.6% this quarter and gained 136.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 2.8% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." 
Wall Street's median 12-month price target for Boundless Bio, Inc. is $4.00, about 29% above its last closing price of $2.84
This summary was machine generated from LSEG data August 7 at 12:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.58
-1.06
Missed
Mar. 31 2026 
-0.58
-0.60
Missed
Dec. 31 2025 
-0.52
-0.58
Missed
Sep. 30 2025 
-0.58
-0.62
Missed